MediPharm Announces Voting Results from the 2025 Annual and Special Meeting of Shareholders

Core Points - MediPharm Labs Corp. held its annual and special meeting where key resolutions were voted on by shareholders [1][2] - A total of 210,726,733 common shares were represented, accounting for 50.76% of the total issued shares [2] - The meeting resulted in the approval of several resolutions including the number of directors, appointment of auditors, election of directors, and unallocated awards under the equity incentive plan [3] Voting Results - The resolution to fix the number of directors at seven was approved with 75.46% voting in favor [5] - All management director nominees were elected with Chris Halyk receiving 144,007,422 votes and Emily Jameson receiving 144,289,930 votes [6] - MNP LLP was appointed as the auditor with 90.78% of votes in favor [7] - The resolution for unallocated awards under the equity incentive plan was narrowly approved with 50.14% voting for and 49.86% against [8] Board Changes - New directors Emily Jameson and John Medland were welcomed to the Board, while Michael Bumby did not stand for re-election [4] Company Overview - MediPharm Labs specializes in the development and manufacture of pharmaceutical-quality cannabis concentrates and advanced derivative products [9] - The company received a Pharmaceutical Drug Establishment License from Health Canada in 2021, making it the only North American company with a commercial-scale GMP license for cannabinoid extraction [10] - In 2023, MediPharm acquired VIVO Cannabis Inc., expanding its reach to medical patients in Canada, Australia, and Germany [11]